Resistance to androgen-pathway drugs in prostate cancer

New England Journal of Medicine

Volumn 371, Issue 23, 2014, Pages 2233-2234

  Şendur, Mehmet A N ^a   Akinci, Muhammed B ^a   Yalçin, Bülent ^a  

^a YILDIRIM BEYAZIT UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR SPLICE VARIANT 7 MESSENGER RNA; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG; ANDROGEN RECEPTOR; ANDROSTANE DERIVATIVE; PHENYLTHIOHYDANTOIN; RNA; ABIRATERONE; ENZALUTAMIDE;

ANDROGEN DEPRIVATION THERAPY; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; HUMAN; LETTER; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; TREATMENT DURATION; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; DRUG RESISTANCE; GENETICS; MALE; PROSTATE TUMOR; DISEASE COURSE; DRUG RESPONSE; PROTEIN ANALYSIS;

ANDROSTENOLS; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; PHENYLTHIOHYDANTOIN; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RNA, NEOPLASM;

EID: 84918790410     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1412594     Document Type: Letter

References (2)

1. Antonarakis ES, Lu C, Wang H, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 2014;371:1028-38.
2. Loriot Y, Massard C, Albiges L, et al. Personalizing treatment in patients with castrate-resistant prostate cancer: a study of predictive factors for secondary endocrine therapies activity. J Clin Oncol 2012;30:Suppl:213. abstract.